Valbiotis Successfully Completes €10.2 Million Capital Increase to Accelerate Growth
Valbiotis announced on Friday the successful completion of its €10.2 million capital increase with the maintenance of preferential subscription rights. This fundraising, 60.85% of which came from subscription requests and 39.2% from guarantee commitments, will finance the commercial acceleration of the French laboratory specializing in natural health solutions.
Funding Aimed at Commercial Expansion
The capital increase of €10.2 million generated a total demand for 7.2 million shares at €0.86 each, representing 60.85% of the maximum amount of 11.84 million shares offered. The subscriptions on an irreducible, reducible, and free basis reached €6.2 million and were fully met. The remaining 4.6 million shares (39.2% of the amount) were allocated to investors who provided guarantee commitments, with an allocation rate of 74.6% of their promises. Among the subscribers is Ximen RD PTE Ltd, a structure 100% owned by Xianhua Tao and holding 51% of the Sino-French joint venture alongside Valbiotis, which committed €2 million. The company's share capital will increase to €3.55 million divided into 35.54 million ordinary shares of €0.10 nominal each after the closing of the operation.
Funds Allocated to Supply Chain and Sales Force
The net proceeds of the operation, estimated at €8.9 million, will be distributed along three strategic axes. Sixty-two percent (approximately €5.5 million) will finance the working capital needs of clients and inventory, primarily securing the supply chain at the factory. Twenty-five percent (€2.2 million) will go towards strengthening the sales force network, increasing from 16 to 25 medical representatives, in order to support revenue growth targets and expand the brand's presence in France. The remaining 13% (€1.2 million) will be dedicated to marketing and communication expenses. According to the statement, the available cash position at the end of April 2026, the expected acceleration of activity according to the already communicated strategic plan, and the financial debt repayment schedule will allow the net cash position to extend beyond the third quarter of 2027. Valbiotis maintains its goal of achieving a positive EBITDA for the fiscal year 2027.
Capital Restructuring and Settlement Schedule
Before the increase, public participation represented 96.09% of the capital. After the closing of the operation, it will move to 90.85%, while Ximen RD PTE Ltd will enter the capital at 6.54%. The float of the directors, including Djanka Investissement (controlled by Sébastien Peltier, chairman of the board and co-founder), will decrease from 3.37% to 2.25% on a non-diluted basis. Sébastien Peltier commits to retaining the shares held via Djanka Investissement for 180 days after the settlement-delivery. The company has also committed to a 180-day standstill period, under usual exceptions. The settlement-delivery and the admission of the new shares for trading on Euronext Growth Paris will take place on June 30, 2026. The new shares will carry current rights and will be immediately assimilated into the existing shares under the same ISIN code (FR0013254851 - Ticker: ALVAL).
